It is noted that APOE genotype regulates pathology and disease progression in synucleinopathy, with APOE ε4 exacerbating pathology and APOE ε2 protecting against α-synuclein aggregation and neurodegeneration [36]. This evidence concerns the gene SNCA and synucleinopathy.